🍄 Именно такие кейсы (https://t.me/LanceBio/259) показывают, почему #Psilocybin & #Psilocin в их нынешнем виде остаются NOT TRUE PHARMA!    💊 Of course, it is worth addressing the safety issues of the base molecule — optimising cost, ADME, synthesizability and binding affinity profile, while accounting for genetic polymorphisms and biased receptor activation / inhibition across tissues. Add to this predictive cardiotoxicity models (hERG, 5-HT2*Rs, sympathomimetic), off‑target binding, pharmacogenomic variability, and delivery strategies (LNPs, liposomes, exosomes, prodrugs, intranasal and other) with in silico BBB transit and release kinetics.    The platform must integrate multi‑objective optimisation (CNS exposure vs systemic burden), synthetic accessibility, and a compliance layer generating dual‑contour outputs (global vs local). Only then can the same scientific core be safely translated across jurisdictions and investing landscapes.    🌵 #COMP360 from Compass is indeed a synthetic, GMP‑grade psilocybin — but the pharmacological limitations of the molecule remain. Without a systemic optimisation layer, even standardized products risk repeating the same cycle of “formally positive, yet disappointing” outcomes.